EXPLEOSOLExpleo Solutions Limited
IT · Information Technology Services · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Expleo Solutions Limited, together with its subsidiaries, primarily provides software validation and verification services to the banking, financial services, and insurance industries worldwide. It offers computer programming, consultancy and related activities, quality management, software development, software testing, digital transformation, product and process engineering, quality & testing, and customer support and maintenance services. It also offers financial services. The company was formerly known as SQS India BFSI Limited and changed its name to Expleo Solutions Limited in April 2019. Expleo Solutions Limited was incorporated in 1998 and is based in Chennai, India. Expleo Solutions Limited Limited is a subsidiary of Expleo Technology Germany GmbH.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on EXPLEOSOL — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Profit growth: 67.3% YoY
- • ROCE: 18.1%
- • Debt/Equity: 0.01
- • Golden cross setup: SMA50 above SMA200
- • 3-month return: +13.2%
- • 3-month vs NIFTY: +17.5% relative
Bull case
- • Profit growth: 67.3% YoY
- • ROCE: 18.1%
- • Debt/Equity: 0.01
- • Golden cross setup: SMA50 above SMA200
Bear case
- • RSI: 35
- • MACD: bearish
- • 1-month return: -7.4%
- • 1-month vs NIFTY: -4.5% relative
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Momentum is fading versus the broader market
- • RSI: 35
- • MACD: bearish
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹29.80). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.